RU2007126552A - NEW SUBSTITUTED THIOPHENPYRIMIDINONE DERIVATIVES AS 17β-HYDROXISTEROID-DEHYDROGENASE INHIBITORS - Google Patents

Claims (26)

1. The new compound of formula (I)

where R1 and R2 are independently selected from the group including (1) —C ₁ -C ₁₂ alkyl, which is straight, cyclic, branched or partially unsaturated, and optionally substituted with one, two or three substituents independently selected from the group consisting of hydroxyl, C ₁ -C ₁₂ alkoxy, thiol, C ₁ -C ₁₂ alkylthio, aryloxy, arylacyl, -CO-OR, -O-CO-R, heteroaryl acyloxy and —N (R) ₂ , wherein said aryl group is phenyl or naphthyl, and is optionally substituted with one, two or three halogen atoms, where the specified heteroaryl group means thienyl, furyl or pyridinyl, (2) aryl and aryl (C ₁ -C ₁₂ ) alkyl, wherein the alkyl is optionally substituted with one or two hydroxyl groups, and where aryl is optionally substituted with one to five substituents independently selected from the group consisting of halogen, hydroxyl, C ₁ -C ₁₂ alkoxy, nitro, nitrile, C ₁ -C ₁₂ alkyl, halogen (C ₁ -C ₁₂ ) alkyl, -SO ₂ -N (R) ₂ , C ₁ -C ₁₂ alkylsulfonyl, or where aryl is optionally substituted with two groups attached to adjacent carbon atoms and forming a saturated cyclic 5-, 6- or 7-membered ring ring system, optionally containing one, two or three heteroatoms, such as N or O, wherein 0-3 their ones can mean a nitrogen atom, and 0-2 of them can mean an oxygen atom, moreover, the cyclic system may be optionally substituted by an oxo group, (3) heteroaryl and heteroaryl (C ₁ -C ₁₂ ) alkyl, wherein the heteroaryl group is optionally substituted with one, two or three substituents independently selected from the group consisting of halogen, C ₁ -C ₁₂ alkyl, halogen (C ₁ -C ₈ ) alkyl, -CO-OR, aryl or aryloxy, where the aryl group is selected from phenyl or naphthyl, and such a group is optionally substituted with one, two or three halogen atoms, (4) cycloheteroalkyl and cycloheteroalkyl (C ₁ -C ₈ ) alkyl, where cycloheteroalkyl is selected from the group consisting of pyrrolidinyl, tetrahydrofuryl, tetrahydrothiophenyl, tetrahydropyridinyl, dioxolyl, azetidinyl, thiazolidinyl, oxazolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, azidezipanediazide-di-azide-di-azide-di-azide-di-azide-di-azide-di-azide-di-azide-di-azide-di-azide-di-azide-di-azide-di-azide-di-azide-di-azide-azide-di-azide-di-azide-di-azide-di-azide-azide , wherein cycloheteroalkyl is optionally substituted with one to two substituents independently selected from the group consisting of oxo, C ₁ -C ₁₂ alkyl, hydroxyl, C ₁ -C ₁₂ alkoxy and aryl (C ₁ -C ₁₂ ) alkyl, or R2 is independently selected from the group including —CO — R, —CO — OR or —CO — N (R) ₂ , wherein R1 and R2 do not simultaneously mean unsubstituted alkyl, R3 and R4 are independently selected from the group consisting of hydrogen, oxo, thio, halogen or dihalogen, —CO — R, preferably CHO, —CO — OR, nitrile, —CO — N (R) ₂ , —O — CO — R, —OR, —SR, —N (R) ₂ , Branched-chain C ₁ -C ₁₂ alkyl, cyclic or partially unsaturated, optionally substituted with one, two or three substituents independently selected from the group consisting of hydroxyl, C ₁ -C ₁₂ alkoxy, thiol and -N (R) ₂ . R5 and R6 are independently selected from the group consisting of hydrogen, halogen, —O — R, —CO — O — R, —CO — R, C ₁ -C ₁₂ straight or branched chain alkyl, cyclic or partially unsaturated, optionally substituted with one, two or three substituents independently selected from the group consisting of hydroxyl, C ₁ -C ₁₂ alkoxy, thiol, C ₁ -C ₁₂ alkylthio and -CO-OR, and aryl and aryl (C ₁ -C ₁₂ ) alkyl, where aryl is optionally substituted with one to five substituents independently selected from the group consisting of halogen, hydroxyl, C ₁ -C ₁₂ alkoxy, nitro, nitrile, C ₁ -C ₁₂ alkyl, halogen (C ₁ -C ₁₂ ) alkyl, moreover, R5 and R6 cannot simultaneously mean hydrogen, and R6 does not mean halogen, if R5 means hydrogen, where R is hydrogen, C ₁ -C ₁₂ alkyl or phenyl, and the phenyl group optionally substituted with one, two or three substituents selected from the group consisting of halogen, hydroxyl and C ₁ -C ₄ alkoxy, and the hydrocarbon chain -C (R3) -C (R4) -C (R5) -C (R6) in The 6-membered ring is saturated or contains one or two carbon-carbon double bonds, or a pharmaceutically acceptable salt thereof. 2. The compound of formula (I) according to claim 1, where the 6-membered ring comprising a hydrocarbon chain —C (R3) —C (R4) —C (R5) —C (R6) - is an aromatic ring. 3. The compound of formula (I) according to claim 1, where the 6-membered cycle comprising the hydrocarbon chain —C (R3) —C (R4) —C (R5) —C (R6) - is other than an aromatic ring . 4. The compound of formula (I) according to claim 1, where R2 is selected from the group including (1) C ₁ -C ₈ straight or branched chain alkyl, cyclic or partially unsaturated, which is optionally substituted with one, two or three substituents independently selected from the group consisting of hydroxyl, C ₁ -C ₈ alkoxy, thiol, C ₁ -C ₈ alkylthio, aryloxy, -CO-O- (C ₁ -C ₈ ) alkyl and -O-CO-R ′, wherein said aryl group is phenyl or naphthyl, optionally substituted with one, two or three halogen atoms, (2) aryl and aryl (C ₁ -C ₈ ) alkyl, where the aryl group is optionally substituted with one to five substituents independently selected from the group consisting of halogen, hydroxyl, C ₁ -C ₈ alkoxy, nitro, nitrile, halogen (C ₁ -C ₈ ) alkyl, -SO ₂ -N (R ′) ₂ , (3) heteroaryl and heteroaryl (C ₁ -C ₈ ) alkyl, wherein the heteroaryl group is optionally substituted with one, two or three substituents independently selected from the group consisting of halogen, C ₁ -C ₈ alkyl, halogen (C ₁ -C ₈ ) alkyl, aryl or aryloxy, where the aryl group is selected from phenyl or naphthyl and optionally substituted with one, two or three halogen atoms, (4) -CO-R ′, (5) -CO-N (R ′) 2, and (6) -CO-O-R ′, where R ′ is hydrogen or C ₁ -C ₈ alkyl. 5. The compound of formula (I) according to claim 4, where R2 means (a) a group of formula (II)

Where R7 is hydrogen, halogen, hydroxyl or C ₁ -C ₄ alkoxy, R8 is hydrogen, C ₁ -C ₄ alkoxy, hydroxyl, nitrile, halogen or halogen (C ₁ -C ₄ ) alkyl, R9 is hydrogen, C ₁ -C ₄ alkoxy, hydroxyl, nitrile, halogen or N, N-di (C ₁ -C ₄ ) alkylsulfonamide, R10 is hydrogen, C ₁ -C ₄ alkoxy, hydroxyl, nitrile, halogen, or halogen (C ₁ -C ₄ ) alkyl, and R11 is hydrogen, halogen, hydroxyl or C ₁ -C ₄ alkoxy, or (b) (1) —C ₁ -C ₈ straight or branched chain alkyl, cyclic or partially unsaturated, (2) —C ₁ C ₄ alkyl substituted with one or two substituents selected from the group consisting of —CO — O — R ″, —O — R ″, O — Ar, where Ar is phenyl optionally substituted with halogen, - O-CO-R ″, phenyl or biphenyl optionally substituted with one, two or three C ₁ -C ₄ alkoxy groups, (3) -CO-O-R '', (4) -CO-R '', (5) naphthyl, (6) heteroaryl, where the heteroaryl group is optionally substituted with one or two substituents independently selected from the group consisting of halogen, C ₁ -C ₄ alkyl, halogen (C ₁ -C ₄ ) alkyl, phenyl and phenoxy, where the phenyl group is optionally substituted with one, two or three halogens, where R "means hydrogen or C ₁ -C ₄ alkyl. 6. The compound of formula (I) according to claim 5, where R2 means (1) —C ₃ -C ₈ straight or branched chain alkyl or cyclic, (2) -C ₁ -C ₄ alkyl optionally substituted with one or two substituents independently selected from the group consisting of C ₁ -C ₄ alkoxy and hydroxyl, (3) phenyl (C ₁ -C ₄ ) alkyl, wherein the phenyl group is optionally substituted with one or two C ₁ C ₄ alkoxy groups, (4) heteroaryl, wherein heteroaryl is selected from the group consisting of furyl, pyridinyl, thienyl, thiazolyl and pyrimidinyl, (5) a group of formula (II)

Where R7 is hydrogen, C ₁ -C ₄ alkoxy or halogen, R8 is hydrogen, halogen, C ₁ -C ₄ alkoxy or hydroxyl, R9 is hydrogen, hydroxyl or C ₁ -C ₄ alkoxy, R10 means hydrogen, halogen, C ₁ -C ₄ alkoxy or hydroxyl, and R11 is hydrogen, C ₁ -C ₄ alkoxy or halogen. 7. The compound of formula (I) according to claim 1, where R1 is selected from the group including (1) —C ₁ -C ₈ straight or branched chain alkyl, cyclic or partially unsaturated, which is optionally substituted with one, two or three substituents independently selected from the group consisting of hydroxyl, C ₁ -C ₈ alkoxy, thiol, -NH ₂ , C ₁ -C ₈ alkylthio, aryloxy, arylacyl, -CO-O- (C ₂ - C ₈ ) alkyl, C ₁ -C ₈ alkylacyloxy, heteroaryl acyloxy and C ₁ -C ₈ alkylamino, wherein said aryl group is phenyl or naphthyl optionally substituted with one, two or three halogens, where the specified heteroaryl group means thienyl, furyl or pyridinyl, (2) aryl and aryl (C ₁ -C ₈ ) alkyl, wherein the alkyl is optionally substituted with one or two hydroxyl groups, and where aryl is optionally substituted with one to five substituents independently selected from the group consisting of halogen, hydroxyl, C ₁ -C ₈ alkoxy, C ₁ -C ₈ alkylsulfonyl, -SO ₂ -N (C ₁ -C ₈ alkyl) ₂ , C ₁ -C ₈ alkyl, halogen (C ₁ -C ₈ ) alkyl, or aryl is optionally substituted by two groups that are attached to adjacent carbon atoms and together form a saturated cyclic 5- or 6-membered ring system, optionally containing one, two or three heteroatoms, such as N or O, and 0-3 of them can mean a nitrogen atom, and 0-2 of them can mean an oxygen atom, moreover, the cyclic ring system may optionally be substituted by an oxo group, (3) heteroaryl and heteroaryl (C ₁ -C ₈ ) alkyl, wherein the heteroaryl group is optionally substituted with one, two, or three substituents independently selected from the group consisting of halogen, C ₁ -C ₈ alkyl, and -CO-O- (C ₁ -C ₈ ) alkyl, (4) cycloheteroalkyl and cycloheteroalkyl (C ₁ -C ₈ ) alkyl, wherein cycloheteroalkyl is optionally substituted with one to two substituents, independently selected from the group consisting of oxo, C ₁ -C ₈ alkyl, hydroxyl, C ₁ -C ₈ alkoxy and aryl (C ₁ -C ₈ ) alkyl. 8. The compound of formula (I) according to claim 7, where R1 is selected from the group including (1) —C ₁ -C ₈ straight or branched chain alkyl or cyclic, (2) —C ₁ -C ₄ alkyl substituted with one or two substituents independently selected from the group consisting of —O — R ″, —O — Ar, —O — CO — HetAr, —CO — Ar, —CO — O -R '' and -N (R``) ₂ , (3) aryl and aryl (C ₁ -C ₄ ) alkyl, wherein the alkyl is optionally substituted with a hydroxyl group, and where aryl is optionally substituted with one, two or three substituents independently selected from the group consisting of halogen, —O — R ″, —SO ₂ —R ″, —SO ₂ —N (R ″) ₂ , or where aryl is optionally substituted with two groups that are attached to adjacent carbon atoms and together form a saturated 5 or 6 membered cyclic ring system, optionally containing up to two oxygen atoms, moreover, the cyclic ring system may optionally be substituted by an oxo group, (4) heteroaryl and heteroaryl (C ₁ -C ₄ ) alkyl, wherein the heteroaryl group is optionally substituted with one or two substituents independently selected from the group consisting of halogen, —C ₁ -C ₄ alkyl, and —CO-OR ”, (5) cycloheteroalkyl and cycloheteroalkyl (C ₁ -C ₄ ) alkyl, wherein cycloheteroalkyl is optionally substituted with one to two substituents independently selected from the group consisting of oxo, C ₁ -C ₄ alkyl, preferably methyl, and-C ₁ -C ₄ alkyl-Ar, where Ar is phenyl optionally substituted with a halogen group or C ₁ -C ₄ alkoxy, HetAr means thienyl, furyl or pyridinyl, and R "means hydrogen or C ₁ -C ₄ alkyl. 9. The compound of formula (I) according to claim 8, where R1 is selected from the group including (1) —C ₁ -C ₄ alkyl optionally substituted with one or two hydroxyl groups, (2) phenyl (C ₁ -C ₄ ) alkyl, wherein the phenyl group is optionally substituted with one or two C ₁ -C ₄ alkoxy groups, or where the phenyl group is substituted by two groups that are attached to adjacent carbon atoms and together form a saturated cyclic 5- or 6-membered ring system, optionally containing one or two oxygen atoms, (3) heteroaryl or heteroaryl (C ₁ -C ₄ ) alkyl, where the heteroaryl group is selected from the group consisting of furyl, pyridinyl, thienyl, thiazolyl and pyrimidinyl, wherein the heteroaryl group is optionally substituted with a C ₁ -C ₄ alkyl group, and (4) cycloheteroalkyl (C ₁ -C ₄ ) alkyl, wherein the cycloheteroalkyl group is selected from the group consisting of tetrahydrofuryl, piperidinyl, morpholinyl and pyrrolidinyl. 10. The compound of formula (I) according to claim 1, where R1 and R2 are independently selected from the group including (1) C ₃ -C ₈ straight or branched chain alkyl or cyclic, (2) -C ₁ -C ₄ alkyl optionally substituted with one or two substituents independently selected from the group consisting of C ₁ -C ₄ alkoxy and hydroxyl, (3) phenyl or phenyl (C ₁ -C ₄ ) alkyl, where the phenyl group is optionally substituted with one to five substituents independently selected from the group consisting of halogen, C ₁ -C ₄ alkoxy and hydroxyl, or where the phenyl group is substituted by two groups that are attached to adjacent carbon atoms and together form a saturated cyclic 5- or 6-membered ring system, optionally containing one or two heteroatoms, such as N or O, (4) heteroaryl or heteroaryl (C ₁ -C ₄ ) alkyl, where the heteroaryl group is optionally substituted with C ₁ -C ₄ alkyl, and (5) cycloheteroalkyl (C ₁ -C ₄ ) alkyl. 11. The compound of formula (I) according to claim 1, where R3 is selected from the group consisting of hydrogen, oxo, —OR ′, —O — Ar, —O — CO — R ′, halogen, thio, —SR ′, and - S-Ar, where R ′ is hydrogen or C ₁ -C ₄ alkyl, and Ar is phenyl optionally substituted with one or more substituents selected from the group consisting of halogen, hydroxyl or C ₁ -C ₄ alkoxy. 12. The compound of formula (I) according to claim 12, wherein R3 is selected from the group consisting of hydrogen, oxo and hydroxyl. 13. The compound of formula (I) according to claim 1, where R4 is selected from the group consisting of hydrogen, C ₁ -C ₄ alkyl optionally substituted with hydroxyl; -CO-R ′, -CO-OR ′, halogen and dihalogen, where R ′ is hydrogen or C ₁ -C ₄ alkyl. 14. The compound of formula (I) according to claim 13, wherein R4 is selected from the group consisting of hydrogen and halogen. 15. The compound of formula (I) according to claim 1, where R5 is selected from the group consisting of hydrogen, —COOR ′, phenyl (C ₁ –C ₄ ) alkyl, C ₁ –C ₄ alkyl, and C ₁ –C ₄ alkyl substituted the group —COOR ′, where R ′ is H or C ₁ -C ₄ alkyl. 16. The compound of formula (I) according to claim 15, wherein R5 is selected from the group consisting of hydrogen, benzyl and C ₁ -C ₄ alkyl. 17. The compound of formula (I) according to claim 1, where R6 is selected from the group consisting of hydrogen, halogen, —OR ′, phenyl (C ₁ -C ₄ ) alkyl, C ₁ -C ₄ alkyl, and C ₁ -C ₄ alkyl substituted by —COOR ′, where R ′ is H or C ₁ -C ₄ alkyl. 18. The compound of formula (I) according to 17, wherein R6 is selected from the group consisting of hydrogen, halogen, benzyl and C ₁ -C ₄ alkyl. 19. The new compound of formula (I) according to claim 1

where R1 and R2 are independently selected from the group including (1) C ₃ -C ₈ straight or branched chain alkyl or cyclic, (2) -C ₁ -C ₄ alkyl optionally substituted with one or two substituents independently selected from the group consisting of C ₁ -C ₄ alkoxy and hydroxyl, (3) phenyl or phenyl (C ₁ -C ₄ ) alkyl, where the phenyl group is optionally substituted with one to five substituents independently selected from the group consisting of halogen, C ₁ -C ₄ alkoxy and hydroxyl, or where the phenyl group is substituted by two groups that are attached to adjacent carbon atoms and together form a saturated cyclic 5- or 6-membered ring system, optionally containing one or two heteroatoms, such as N or O, (4) heteroaryl or heteroaryl (C ₁ -C ₄ ) alkyl, where the heteroaryl group is optionally substituted with C ₁ -C ₄ alkyl, and (5) cycloheteroalkyl (C ₁ -C ₄ ) alkyl. R3 is selected from the group consisting of hydrogen, oxo and hydroxyl, R4 is selected from the group consisting of hydrogen and halogen, R5 is selected from the group consisting of hydrogen, phenyl (C ₁ -C ₂ ) alkyl, C ₁ -C ₄ alkyl, and-C ₁ -C ₄ alkyl-CO-O- (C ₁ -C ₄ ) alkyl, and R6 is selected from the group consisting of hydrogen, halogen, phenyl (C ₁ -C ₂ ) alkyl, C ₁ -C ₄ alkyl and-C ₁ -C ₄ alkyl-CO-O- (C ₁ -C ₄ ) alkyl. 20. A new compound of formula (I) according to claim 19, where R1 is selected from the group consisting of (1) —C ₁ -C ₄ alkyl optionally substituted with one or two hydroxy groups, (2) phenyl (C ₁ -C ₄ ) alkyl, wherein the phenyl group is optionally substituted with one or two C ₁ -C ₄ alkoxy groups, or where the phenyl group is substituted by two groups that are attached to adjacent carbon atoms and together form a saturated cyclic 5- or 6-membered ring system, optionally containing one or two oxygen atoms, (3) heteroaryl or heteroaryl (C ₁ -C ₄ ) alkyl, where the heteroaryl group is selected from the group consisting of furyl, pyridinyl, thienyl, thiazolyl and pyrimidinyl, wherein the heteroaryl group is optionally substituted with a C ₁ -C ₄ alkyl group, and (4) cycloheteroalkyl (C ₁ -C ₄ ) alkyl, where a cycloheteroalkyl group is selected from the group consisting of tetrahydrofuryl, piperidinyl, morpholinyl and pyrrolidinyl, and where R2 is selected from the group comprising (1) C ₃ -C ₈ straight or branched chain alkyl or cyclic, (2) -C ₁ -C ₄ alkyl optionally substituted with one or two substituents independently selected from the group consisting of C ₁ -C ₄ alkoxy and hydroxyl, (3) phenyl (C ₁ -C ₄ ) alkyl, wherein the phenyl group is optionally substituted with one or two C ₁ -C ₄ alkoxy groups, (4) heteroaryl, where the heteroaryl group is selected from the group consisting of furyl, pyridinyl, thienyl, thiazolyl and pyrimidinyl, (5) a group of formula (II)

Where R7 is hydrogen, halogen or C ₁ -C ₄ alkoxy, R8 is hydrogen, halogen, C ₁ -C ₄ alkoxy or hydroxyl, R9 is hydrogen, hydroxyl or C ₁ -C ₄ alkoxy, R10 means hydrogen, halogen, C ₁ -C ₄ alkoxy or hydroxyl, and R11 is hydrogen, halogen or C ₁ -C ₄ alkoxy. 21. A new compound of formula (I) according to claim 1, selected from the group inclusive 3-benzyl-5-methyl-2- (3,4,5-trimethoxyphenyl) -5,6,7,8-tetrahydro-3H-benzo [4,5] thieno [2,3-d] pyrimidin-4- it, 3-benzyl-5-methyl-2- (3,4,5-trimethoxyphenyl) -6,7-dihydro-3H, 5H-benzo [4,5] thieno [2,3-d] pyrimidin-4,8- dion 3-benzyl-7-bromo-2- (2-bromo-3,4,5-trimethoxyphenyl) -5-methyl-6,7-dihydro-3H, 5H-benzo [4,5] thieno [2,3- d] pyrimidine-4,8-dione, 3-benzyl-2- (2-bromo-3,4,5-trimethoxyphenyl) -8-hydroxy-5-methyl-3H-benzo [4,5] thieno [2,3-d] pyrimidin-4-one, 3-benzyl-6-methyl-2- (3,4,5-trimethoxyphenyl) -5,6,7,8-tetrahydro-3H-benzo [4,5] thieno [2,3-d] pyrimidin-4- it, 3-benzyl-6-methyl-2- (3,4,5-trimethoxyphenyl) -6,7-dihydro-3H, 5H-benzo [4,5] thieno [2,3-d] pyrimidin-4,8- dion 3-benzyl-7-bromo-6-methyl-2- (2-bromo-3,4,5-trimethoxyphenyl) -6,7-dihydro-3H-benzo [4,5] thieno [2,3-d] pyrimidine-4,8-dione, 3-benzyl-2- (2-bromo-3,4,5-trimethoxyphenyl) -8-hydroxy-6-methyl-3H-benzo [4,5] thieno [2,3-d] pyrimidin-4-one, 3-butyl-6-methyl-2- (3,4,5-trimethoxyphenyl) -5,6,7,8-tetrahydro-3H-benzo [4,5] thieno [2,3-d] pyrimidin-4- it, 3-butyl-6-methyl-2- (3,4,5-trimethoxyphenyl) -6,7-dihydro-3H, 5H-benzo [4,5] thieno [2,3-d] pyrimidin-4,8- dion 3-butyl-7-bromo-6-methyl-2- (2-bromo-3,4,5-trimethoxyphenyl) -6,7-dihydro-3H-benzo [4,5] thieno [2,3-d] pyrimidine-4,8-dione, 3-butyl-2- (2-bromo-3,4,5-trimethoxyphenyl) -8-hydroxy-6-methyl-3H-benzo [4,5] thieno [2,3-d] pyrimidin-4-one, 2- (2-bromo-3-hydroxy-4,5-dimethoxyphenyl) -3-butyl-8-hydroxy-6-methyl-3H-benzo [4,5] thieno [2,3-d] pyrimidin-4- it, 2- (2-bromo-3,4-dihydroxy-5-methoxyphenyl) -3-butyl-8-hydroxy-6-methyl-3H-benzo [4,5] thieno [2,3-d] pyrimidin-4- it, 7-bromo-3-butyl-2- (2-bromo-3,4,5-trimethoxyphenyl) -8-hydroxy-6-methyl-3H-benzo [4,5] thieno [2,3-d] pyrimidine- 4th, and 7-bromo-2- (2-bromo-3-hydroxy-4,5-dimethoxyphenyl) -3-butyl-8-hydroxy-6-methyl-3H-benzo [4,5] thieno [2,3-d] pyrimidin-4-one, or a pharmaceutically acceptable salt thereof. 22. The compound of formula (I) according to any one of claims 1 to 21 for use as a medicine. 23. The use of the compounds of formula (I) according to any one of claims 1 to 21 for the treatment or prevention of a disease or disorder dependent on a steroid hormone. 24. The use of a compound of formula (I) according to any one of claims 1 to 21, for the manufacture of a medicament for the treatment or prevention of a disease and / or disorder dependent on a steroid hormone. 25. The use according to claim 23 or 24, wherein the steroid hormone dependent disease or disorder means a disease or disorder that requires the inhibition of the enzyme 17β-hydroxysteroid dehydrogenase, preferably 17β-HSD type 1, 17β-HSD type 2 or 17β-HSD type 3. 26. The application of claim 23 or 24, wherein the disease or disorder dependent on the steroid hormone is selected from the group consisting of breast cancer, prostate cancer, ovarian cancer, uterine cancer, endometrial cancer, endometrial hyperplasia, endometriosis, uterine fibroids, uterine leiomyoma, adenomyosis, dysmenorrhea, hypermenorrhea, metrorrhagia, prostadinia, benign prostatic hyperplasia, prostatitis, acne, seborrhea, hirsutism, androgenetic alopecia, precocious puberty, adrenal hyperplasia, with ndrom polycystic ovary, urinary tract dysfunction, osteoporosis, disseminated